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pharmacologic targeting of 
β-catenin improves fracture  
healing in old mice
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β-catenin protein needs to be precisely regulated for effective fracture repair. The pace of fracture 
healing slows with age, associated with a transient increase in β-catenin during the initial phase of 
the repair process. Here we examined the ability of pharmacologic agents that target β-catenin to 
improve the quality of fracture repair in old mice. 20 month old mice were treated with Nefopam or the 
tankyrase inhibitor XAV939 after a tibia fracture. Fractures were examined 21 days later by micro-CT 
and histology, and 28 days later using mechanical testing. Daily treatment with Nefopam for three 
or seven days but not ten days improved the amount of bone present at the fracture site, inhibited 
β-catenin protein level, and increased colony forming units osteoblastic from bone marrow cells. At 28 
days, treatment increased the work to fracture of the injured tibia. XAV939 had a more modest effect 
on β-catenin protein, colony forming units osteoblastic, and the amount of bone at the fracture site. 
this data supports the notion that high levels of β-catenin in the early phase of fracture healing in old 
animals slows osteogenesis, and suggests a pharmacologic approach that targets β-catenin to improve 
fracture repair in the elderly.
Almost a third of humans will fracture a bone, and most often these injuries go on to successfully heal. However, a 
lack of healing (fracture nonunion) is estimated to occur in over 5% of injuries, depending on the anatomic loca-
tion1. Effective bone regeneration relies on the inflammatory response to tissue injury and the physiology of bone 
development. Various environmental and biological factors can hinder this regenerative process2. With age, the 
pace of fracture repair slows, and the risk of non-union increases3,4. This slower pace of repair in older individuals 
is responsible for increased morbidity and even mortality5.
While there are many factors that could impair fracture healing with aging, the pace of fracture repair can 
be rejuvenated by circulating factors present in young animals6. Recent data suggests that factors produced by 
young macrophage cells pay a critical role in the rejuvenation process7. While these factors regulate the pace of 
repair, their effects on mesenchymal cells differentiating to osteoblasts are mediated by signaling pathways such 
as β-catenin. β-catenin signaling plays different roles in mesenchymal differentiation at different repair stages. In 
the initial phase of repair, the level of β-catenin needs to be precisely regulated as levels that are too high or too 
low will prevent undifferentiated mesenchymal cells from becoming osteochondral progenitors and will inhibit 
fracture healing. Once the cells differentiate to osteochondral progenitors, higher levels of β-catenin stimulate 
osteogenesis and enhance fracture repair8,9.
Data from studies in mice shows that older animals have a higher level of β-catenin protein during the early 
phase of fracture repair. Genetic inhibition of β-catenin activation rejuvenates the fracture phenotype in older 
mice6. This is in contrast to data from young mice, in which inhibition of β-catenin impairs fracture healing8. 
Since β-catenin protein level regulates the capacity of undifferentiated mesenchymal cells to become osteochon-
dral progenitors, an elevated protein level in older animals will prevent this differentiation and instead cells will 
maintain a fibroblastic like phenotype. Such a cell type will not contribute to normal fracture repair. Thus, in older 
animals but not younger animals lowering β-catenin protein level at the initial phases of repair will increase the 
proportion of undifferentiated mesenchymal cells at the fracture that can go on to become osteoblasts and heal 
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the injury. In the later phases of the repair process, β-catenin is required for osteoblastic differentiation. Targeting 
β-catenin to effectively improve healing in old animals would need to focus on the earlier phases of the repair 
process.
The ability of pharmacologic agents to improve fracture repair by targeting β-catenin in is not known. 
Nefopam is one agent that is capable of targeting β-catenin in mesenchymal cells10. It is a non-opioid analgesic of 
the benzoxazolcine family of compounds. This agent has minimal side effects and is used in clinical settings across 
Europe and Asia11. Although the mechanisms of action of Nefopam is not fully understood, its use decreased 
β-catenin levels in hypertrophic scar and desmoid tumors10. Another class of agents that can inhibit β-catenin are 
tankyrase inhibitors. XAV939 binds the tankyrase catalytic poly-ADP-ribose polymerase (PARP) domain, and 
subsequently increases β-catenin destruction through stabilization of Axin. It has been utilized as an inhibitor 
of β-catenin in-vivo12–15. Here we examined the ability of Nefopam and XAV939 in the early phases following a 
fracture to improve fracture repair in elderly mice.
Results
Nefopam treatment stimulates ossification during fracture repair in 20 month old mice. To 
determine if pharmacologic modulation of β-catenin might improve fracture repair in older animals, twenty-
month-old male mice were treated with nefopam after generating a tibia fracture. The inflammatory phase of 
fracture repair in mice occurs during the first three days, and the initially proliferative phase when osteochon-
dral progenitors are present occurs at 7 days. Previous studies in mice found that β-catenin protein levels were 
increased at 3 and 7 days following a fracture, and returned towards baseline levels by 10 days9, The 3 and 7 day 
time frame is also the period in which β-catenin protein levels are even higher in older animals6. Thus, we selected 
time frames to test the drug when we knew β-catenin protein levels were elevated, as well as one longer duration 
time point (treatment with nefopam from 3 to 10 days). Treatment was carried out using a dose known to inhibit 
β-catenin in mesenchymal cells16. Control mice were treated with carrier alone for the same time interval. At 21 
days after fracture, the mice were sacrificed and bones analyzed histologically and by μCT. There were no signif-
icant differences in μCT parameters, histomorphometric parameters, or mechanical properties for the carrier 
controls treated for 3, 7, or 10 days. Treatment with Nefopam for 3 or 7 days improved the bone volume/total 
volume and the relative density at the fracture site, while mice treated with Nefopam for 10 days displayed little 
difference compared to controls (Fig. 1A,B). Histomorphometry was undertaken from sections from the fracture 
calluses stained with Safranin O/Fast Green. Three days of Nefopam treatment resulted in an increase in bone 
at the fracture site and a decrease in fibrotic tissue. With seven days of treatment there was an increase in bone 
as well, but not a significant change in fibrous tissue proportion compred to controls. There was not a significnat 
difference between ten day treated mice and controls (Fig. 1C,D). Thus, short term but not longer term treatment 
increased ossification at the fracture site. We did not observe any change in μCT parameters in the unfractured 
bone (supplementary data). This is not unanticipated, given the short duration of drug therapy. There were no 
side effects observed in these mice as well, and there was no difference in the weight of the mice between treated 
and control animals.
Nefopam decreases β-catenin protein level and increases osteoblastic differentiation in old 
mice. Nefopam might alter fracture repair without regulating β-catenin. We thus examined protein expres-
sion in-vivo and osteoblast differentiation in-vitro. Western blot analysis was employed to quantify levels of 
β-catenin protein and activated β-catenin protein. Data was compared with fracture callous in young, 4 month 
old, mice. There was an increase in total and active β-catenin protein in callouses from old mice, and treatment 
with nefopam for three days substantially reduced the total and active β-catenin protein level in calluses from old 
mice (Fig. 2A,B). Colony forming units osteoblastic (CFU-O) derived from 20 month old mice were evaluated to 
investigate osteoblast differentiation after Nefopam treatment. Bone marrow from tibiae were flushed and plated 
for culture following 3 days of Nefopam treatment. There was a significantly greater number of CFU-O in cultures 
from mice treated with Nefopam compared to controls (Fig. 2C,D). There was also a higher level of expression 
of genes important in osteogenesis (supplementary data). Taken together, this supports the notion that Nefopam 
exerts its effects by modulating β-catenin to the optimal level to stimulate mesenchymal cells differentiating to 
osteoblasts.
Tankyrase inhibition increases ossification after fracture in 20 month old mice. To determine 
if other agents that inhibit β-catenin might regulate fracture healing in old mice, we investigated the tankyrase 
inhibitor XAV939. Mice were treated for 3 or 7 days after fracture with a previously established effective dose13,15, 
and compared to carrier controls 21 days after fracture. μCT analysis showed that XAV939 treatment did not 
significantly increase ossification (Fig. 3A,B). Histomorphometry, however, showed a significant increase in bone 
and a decrease in fibrous tissue at the fracture sites (Fig. 3C,D). We then analyzed β-catenin protein levels and 
the ability of mice to form CFU-O. XAV939 had a more modest effect on β-catenin and CFU-O compared to 
nefopam treatment (Fig. 3F,F). This data is consistent with the notion that the less effective ability of XAV939 
to lower β-catenin is the reason that the effect on fracture repair was relatively modest. Because drugs might 
have deleterious systemic effects on which might alter fracture repair, we examined the weight of the mice and 
observed them for signs of distress. There was no evidence of distress or side effects in the mice, and no differ-
ence in weight between the treated mice and controls. Tankyrase inhibitors might inhibit osteoclasts17, and we 
analyzed TRAP stained cells in the various mice. There was no difference in osteoclast numbers in treated mice 
compared to controls (supplementary data).
Nefopam treatment improves the work to failure in healing tibia fractures in old mice. The 
ultimate goal of fracture repair is to reconstitute the mechanical properties of the injured bone. To determine if 
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Nefopam treatment would improve the mechanical properties of the fractured bone, we measured the work to 
failure 4 weeks after injury and compared this to unfractured bone. There was a significant decline in work to 
failure in the healing control bone compared to uninjured bone. However, there was an increase in the work to 
Figure 1. Nefopam treatment increases osteogenesis during fracture healing in old mice. (A) Representative 
micro-CT images of healing tibia fractures 21 days after fracture was generated. (B) Graphical representation 
of relative density or bone volume/total volume (BV/TV) in %. Each data point is shown as well as means and 
95% confidence intervals. An asterisk over a data point indicates a significance p <  0.05 compared to control, 
comparison using ANOVA. (C) Representative histologic images from the tibia of an old mouse 21 days after 
fracture. (D) Graphical representation of percent fibrosis, cartilage, or bone. Each data point is shown as well as 
means and 95% confidence intervals. An asterisk over a data point indicates a significance p <  0.05 compared to 
controls, comparison using Kruskal-Wallis.
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failure in healing fractures in bone from Nefopam treated mice (Fig. 4). The work to failure in the healing bone 
from Nefopam treated mice approached that of the uninjured tibia. The observed increased bone density in heal-
ing fractures in Nefopam treated mice results in a significant increase in bone strength as well.
Figure 2. Nefopam modulates β-catenin during fracture repair and increases colony forming units osteoblastic 
in old mice. (A) Representative Western blot for β-catenin, active β-catenin, and β-actin as a loading control 
from protein extracts from healing tibia fractures in 20 month old mice treated with nefopam or control, 
or young mice as a reference. Each set of bands for each protein is from a single blot, with the full blot 
shown in supplementary data. The loading control is from a stripped and probed membrane. (B) Graphical 
representation of relative β-catenin level, with controls arbitrarily averages to “1.” Each data point is shown 
as well as means and 95% confidence intervals. An asterisk over a data point indicates a significance p <  0.05 
compared to controls, comparison using. (C) Representative Colony forming units osteoblastic (CFU-O) from 
bone marrow from mice treated with nefopam or controls. (D) Graphical representation of relative CFU-O, 
with controls arbitrarily averages to ‘1.” Each data point is shown as well as means and 95% confidence intervals. 
An asterisk over a data point indicates a significance p <  0.05 compared to controls, comparison using t-test.
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Discussion
Prior work suggests that high levels of β-catenin in older animals impairs osteoblastic differentiation6. Our data 
supports this notion but also shows that short-term, but not longer term, β-catenin inhibition improved the qual-
ity of bone repair in older mice. Nefopam is an agent used in patients with an established safety record10,11. Here 
we identified a potential repurposed use for a drug in bone repair in situations in which β-catenin protein levels 
are elevated, and show that agents that target β-catenin may serve as a novel pharmacologic approach to improve 
healing in the elderly.
Figure 3. Tankyrase inhibition increases osteogenesis during fracture healing in old mice. (A) Representative 
micro-CT images of headlining tibia fractures 21 days after fracture. (B) Graphical representation of relative 
density or bone volume/total volume (BV/TV) in %. Each data point is shown as well as means and 95% 
confidence intervals. (C) Representative histologic images from the tibia of an old mouse 21 days after fracture. 
(D) Graphical representation of percent fibrosis, cartilage, or bone. Each data point is shown as well as means 
and 95% confidence intervals. An asterisk over a data point indicates a significance p <  0.05 compared to 
controls.
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XAV939 also will target β-catenin. XAV939 treatment did not have a strong an effect on either β-catenin 
or on osteogenesis during fracture repair as Nefopam. This supports the notion that targeting β-catenin is the 
mechanism of action for improving fracture repair. Inactivation of tankyrase also targets osteoclasts and can 
produce low bone density. XAV939 did not have an effect on osteoclast numbers, and likely the duration of use 
was too short to result in a phenotypic change. While toxicity is a concern when inhibiting β-catenin signaling 
pathway18,19, both nefopam and XAV939 are reported to have mild side effects, At the doses we utilized for the 
short duration, side effects such as weight loss and diarrhea were not observed in the animals.
Similar to the situation in aging, mice lacking Nf1 also exhibit high levels of β-catenin in the early phases of 
healing fractures20. Short term nefopam treatment in mice lacking Nf1 improves ossification at the fracture site16. 
In these studies, nefopam was also used for short periods of time in young control mice, and these mice did not 
show any difference in the fracture repair phenotype16. Our finding in aging, extends the role of nefopam as a 
modulator of osteoblastic differentiation and bone fracture repair in instances in which β-catenin protein is ele-
vated. Aging and neurofibromatosis are two such instances.
One potential limitation of this study is that we examined only male mice. However, previous work found no 
differences in fracture repair parameters between male and female 20 month old C57BL6 mice6,7. We are under-
taking a variety of studies examining repair in older animals in our research group, including parabiosis work. 
Because female mice are preferable for parabiosis work, as they adjust to the conditions better than male mice6, 
we preferentially used the female mice for that work. In order to minimize the number of animals bred for this 
research, and because there are no reported differences in repair parameters between male and female mice, we 
used male mice from our colony for this work.
The data in this study suggest a possible pharmacologic approach to the rejuvenation of fracture healing in 
old mice via modulation of β-catenin. Short term inhibition during the initial phases of fracture healing, a time 
when undifferentiated mesenchymal cells can differentiate to osteochondral progenitors, is most effective. Such a 
non-invasive, short term pharmacologic approach with low side effects has obvious advantages over more inva-
sive approaches to stimulate fracture healing. While we used injection of the drugs in this study to better control 
dosing, nefopam and tankyrase inhibitors are available as oral agents, and could be administered via an oral route 
in a clinical trial.
Figure 4. Nefopam treatment improves mechanical properties of healing fractures in 20 month old mice. (A) 
Graphical representation of bone volume/total volume (BV/TV) in % for mice 28 days after a fracture. Each 
data point is shown as well as means and 95% confidence intervals. An asterisk over a data point indicates a 
significance p <  0.05 compared to control, comparison using t-test. (D) Graphical representation of work to 
fracture of two different durations of treatment. Each data point is shown as well as means and 95% confidence 
intervals. An asterisk over a data point indicates a significance p <  0.05 compared to controls, comparison using 
Kruskal-Wallis.
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Materials and Methods
Mice and treatments. Animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC) at Duke University. Experiments were performed in compliance with NIH guidelines 
on the use and care of laboratory and experimental animals. C57BL6 mice were provided from Charles River 
Laboratories (Wilmington, MA, USA) and housed under a 12-hour light, 12-hour dark cycle. Food and water 
were provided ad libitum. Male mice were used for the study based on our previous data showing that old male 
and female C57BL6 mice have identical fracture repair characteristics6,7. Nefopam hydrochloride was purchased 
from MedChemExpress (Monmouth Junction, NJ, USA) and dissolved in normal saline as carrier control, then 
delivered by intraperitoneal injection (i.p.) (30 mg/kg). XAV939 was purchased from Selleck (Houston, TX, USA) 
and dissolved in 4% dimethyl sulfoxide (DMSO). Corn oil was used for vehicle or carrier control. XAV939 was 
subsequently delivered by i.p. injection (20 mg/kg). Mice were randomly selected to either receive treatment or 
carrier. Treatment was started from the day of surgery and progressed at a duration of 3, 7, or 10 days. Doses were 
selected from prior studies. Animals were observed for any deleterious symptoms and their weight was recorded 
before, during and after treatment.
Fracture generation. A tibia fracture with intramedullary stabilization was used to study bone repair8. 
Briefly after anesthesia was induced, the surgical area was shaved and disinfected. A 3-mm longitudinal incision 
was made in the patella tendon and 0.5mm hole was drilled by a 25G syringe needle above the tibial tuberosity. 
Intramedullary fixation was achieved using a 0.7 mm insect pin then the mid-tibial diaphysis was transected with 
small surgical scissors. Osteotomies were made parallel to the tibial plateau. The incision was then closed using 
sutures. Analgesia was provided to all mice. As in our prior work6–8,16,20. Slow release buprenorphine hydrochlo-
ride analgesia (0.03 mg/kg). was provided as an analgesic during the generation of a tibial injury and the initial 
painful period after the fracture was generated until animals returned to their usual activity level.
Radiograph and μCt analyses. The fractured tibia, as well as, and the intact, contralateral tibiae were 
studied after mice were sacrificed at postoperative 21 days. Tibiae were then fixed in 10% formalin for 48 h at 
room temperature (25 °C) and then transferred to 70% ethanol. Implants were removed from the tibiae prior to 
scanning. The quality of fracture repair was assessed using the Faxitron MX20 X-ray system (Faxitron, Tucson, 
AZ, USA). Quantitative three-dimensional evaluation of the fracture callus and healing was undertaken by μCT 
using a Viva CT 80 (Scanco, Brüttisellen, Switzerland) at 55 kVp and 145 μA with a resolution of 15.6 μm voxel 
size. A hydroxyapatite calibration phantom was used to scale values of linear attenuation for the calcified tissues to 
bone density values (mg/cm3). Morphometric parameters were quantified21 at the site of fracture which included 
1mm proximal and distal from the fracture location. The original grayscale image datasets of the tibia region of 
interest were imported into the manufacturer software and the cortical and callus regions were separated using 
an automated contouring method. Calcified tissues were segmented from soft tissues using a global thresholding 
procedure with a threshold of 480 mg HA/cm3, which represents 45% of the attenuation of mature cortical bone 
(19, 20). Callus maturity was measured using differential thresholding in which immature bone was defined by a 
threshold of 169 to 400 mg HA/cm3. As an additional analysis, the unfractured tibia was also examined using μCT. 
Parameters such as Bone volume/total volume in the tibia were analyzed using ASBMR guidelines22.
Histology and histomorphometry. After the μCT imaging process, tibiae were decalcified in 14% EDTA 
(pH 7.4) for 7 days at room temperature. Decalcified samples were dehydrated in a graded ethanol series, embed-
ded into paraffin. Sections 5 µm thick were prepared and stained using Safranin-O (to stain proteoglycans/carti-
lage red) and counterstained with Fast Green (to stain bone green/blue). For evaluation of osteoclastogenesis, the 
formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells was visualized by TRAP 
staining (Sigma-Aldrich). The sections were examined and photographed using a Leica digital imaging system 
(Leica, Wetzlar, Germany). Histomorphometry measurements were quantified using ImageJ software (National 
Institutes of Health, USA).
protein and RNA analysis. Bone fragments were collected from the tibia from mice treated with carrier, 
Nefopam, or XAV939, harvested on the day 3 of treatment. After dissection, the harvested tissues were immedi-
ately frozen in liquid nitrogen, pulverized then homogenized in radioimmunoprecipitation assay (RIPA) buffer 
(Thermo Fisher Scientific). Total protein was quantified with Bradford reagent using a bovine serum albumin 
(BSA) standard curve as a reference. SDS-polyacrylamide gels at 8% concentration were loaded with 25 µg of pro-
tein lysate. Anti-β-catenin antibody (AB19022) was purchased from Millipore, an antibody that recognizes acti-
vated (unphosphorylated at Ser-37 and Thr-41) β-catenin (clone 8E7) was also obtained from Millipore and an 
anti-β-actin (13E5) antibody was purchased from Cell Signaling and was probed as a loading control. Indicated 
antibodies were detected using horseradish peroxidase-conjugated secondary antibodies and ECL chemilumi-
nescence (Bio-Rad). Protein expression was analyzed by measuring the intensity of detected bands compared to 
intact tibia samples and normalized to β-actin with ImageJ software. RNA was extracted from CFU cell cultures 
using Trizol (Invitrogen) and cDNA was generated with Superscript II (Invitrogen). For real-time reverse tran-
scriptase PCR (RT-PCR), mouse–specific Taq-Man fluorogenic probes for alkaline phosphatase, collagen type 
I, osteocalcin, and osteopontin were used. Asparagine synthetase and glyceraldehyde-3-phosphate were used as 
internal control genes.
Cell culture. Unfractured tibia of 20-month old mice was isolated and contents of medullary cavity (bone 
marrow) were flushed using αMEM culture medium (Gibco) on POD 21 days. Cell suspensions were passed 
through an 18G needle to dissociate cell aggregates, and cells were plated in 24-well plates with a density of 5 × 105 
cells/ml in plating medium (αMEM, 10% FBS, 1% Penicillin/Streptomycin) or 1 × 106 cells/ml for seven days. To 
determine the colony forming units-fibroblastic after14 days with plating media; wells were then washed with 
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PBS, fixed with 10% formalin, and stained with 0.05% crystal violet. Cells were cultured in osteogenic differenti-
ation media (αMEM, 10% FBS, 1% Penicillin/Streptomycin, 30 uM ascorbic acid, 10–8 M dexamethasone, 8 mM 
sodium phosphate) for next 14 days. Cultures were incubated for 21 days at 37 °C with 5% CO2 and media were 
replenished every 2 days. Wells were washed with PBS, fixed using 10% formalin, and stained for alkaline phos-
phatase (ALP) using NBT/BCIP and mineralization using 2.5% silver nitrate solution (Von Kossa) on a light box 
and 2% Alizarin Red S (pH 4.3). Colonies were defined by containing at least 25 cells.
Mechanical testing to determine work to failure. Tibiae for mechanical testing were harvested four 
weeks following the generation of a Fracture. Intact tibiae were harvested, soft tissue removed, and immediately 
wrapped in PBS soaked gauze and then frozen at −20 °C. The limbs were thawed prior to mechanical testing. This 
process has been shown to be the best method of preservation of mechanical properties in bone. The inherent 
variability in mechanical testing was found to be greater than any loss in bone properties due to the process-
ing23–25. Tibia were tested to failure in four-point bending on a Precision Materials testing machine (Acumen 3 
A/T, MTS, Eden Prairie, MN) with a 500N force transducer (model 661.11H.02, MTS, Eden Prairie, MN). The 
supports of the four-point bend fixture were cylindrical and 2 mm in diameter. The distance between the mid-
points of the lower load supports was set to 8.9 mm, and the distance between the midpoints of the upper load 
supports was set to 4 mm, spanning the fracture callus and centered over the lower supports. Tibiae were loaded 
by a flexion moment with the flat anteromedial surface down26 on the lower supports at a constant displacement 
rate of 0.03 mm/s27 to failure. The data acquisition rate for load, displacement, and time was 20 Hz. Failure loads 
were calculated using a peak-prominence calculation in MatLab. A prominence of 0.25 was used for intact con-
tralateral tibia and 0.4 for fractured tibia. Failure loads were then confirmed visually as the primary departure of 
a linear trend of the load-displacement data. Bending stiffness was calculated as the slope of the load v. displace-
ment data between 30–70% of the load at failure to exclude the nonlinear toe-regions. Energy to failure (mJ) was 
calculated using a trapezoidal algorithm of the area under the load-displacement curves.
statistical analysis and data sharing. A priori power analysis to obtain statistical significance (p = 0.05, 
power 80%) between the two groups. Sample sizes were determined using a power calculation based on variances 
from prior investigations: Micro-computed-tomography (μCT) imaging, n ≥ 7 per group on day 21; histology, 
n ≥ 7 per group on day 21; colony forming unit (CFU), n ≥ 3 per group on days 21; western blot, n ≥ 3 per group 
on days 3. μCT and histology data were analyzed in a blinded manner. Data are expressed as the means ± 95% 
confidence intervals. The Bartlett test was used to determine if the comparison groups followed a normal distribu-
tion. If the Bartlett test showed that the variances equal statistical significance was evaluated through a Student’s 
t-test for all comparisons in which there were two groups; or a one-way analysis of variance (ANOVA) followed by 
a Turkey post hoc testing for analyses in which there were three or more comparisons being made. If Bartlett test 
showed that the variances were not parametric, the Kruskal-Wallis test to test for differences in population means 
instead of ANOVA and the Steel-Dwass test was used instead of Turkey28,29. The data shown in Figs 1D and 4B 
was analyzed using a non-parametric approach. The data differences were considered significant at p < 0.05. 
GraphPad software was used for analysis (GraphPad Software, San Diego, CA). The datasets generated during 
and/or analyzed during the current study are available from the corresponding author on reasonable request.
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